|
Original Publications
| Frank Petrak, PhD, Stephan Herpertz, MD,
Elmar Stridde, MD, and Andreas Pfützner, MD;
Psychological Insulin Resistance in Type 2 Diabetes Patients Regarding Oral
Antidiabetes Treatment, Subcutaneous Insulin Injections, or Inhaled Insulin;
Diabetes Technology & Therapeutics 2013, 15 (8), 702-710 |
| Huppertz E, Pieper L, Klotsche J, Stridde E,
Pittrow D, Böhler S, Lehnert H.
Diabetes Mellitus in German Primary Care: quality of glycaemic control
and subpopulations not well controlled - results of the DETECT study.
Exp Clin Endocrinol Diabetes. 2009 Jan;117(1):6-14 |
| Petrak F, Stridde E, Levrekus F, Crispin A,
Forst T, Pfüzner A;
Development and validation of a new measure to evaluate psychological
resistence to insulin treatment; Diab. Care 2007; 30, 2199-2205 |
| Pfüzner A, Pfüzner AH, Stridde E,
Huppertz E, Reimer T, Derwahl M, Petrak F; Insulin resistance
and beta-cell-disfunktion in insufficiently controlled type 2 diabetes:
the SETT2D trial; Diabetes, Stoffwechsel und Herz 2007; 2, 91-97 |
| Freemantle N, Blonde L, Ross S, Martinez L,
Stridde E; Availability of inhaled insulin promots greater
perceived acceptance of insulin therapy in patients with Type 2 diabetes;
Diab. Care 2005; 28, 427-428 |
| Wigand, R., Wehling, M., Brauer, H.G., Stridde, E.,
Vergin, H., May, M.; Celecoxib in the symptomatic treatment of active
osteo- or rheumatoid arthritis; Dtsch Med Wochenschr 129,1188-1192, 2004 |
| Fuder H, Kleist P, Birkel M, Ehrlich A,
Emeklibas S, Maslak W, Stridde E, Wetzelsberger N, Wieckhorst G,
Lücker PW; The alpha-glucosidase inhibitor voglibose (AO-128)
does not change pharmacodynamics or pharmacokinetics of warfarin; Eur J
Clin Pharmacol 1997; 59: 153-157 |
| Nauck M, März W, Kleist P, Stridde E, Wieland H;
The influence of voglibose and acarbose on plasma lipids in NIDDM patients
in the fasting and postprandial state; Atheriosclerosis 1997; 134: 313 |
| Göke B, Fuder H, Wieckhorst G, Theiss U,
Stridde E, Littke T, Kleist P, Arnold R, Lücker PW; Voglibose (AO-128)
is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous
GLP-1 reserve; Digestion 1995; 56: 493-501 |
| Michiels I, Schmitz B, Stridde E;
Die Spül-Saug-Drainage und Synovectomie in der Behandlung des
Kniegelenkempyems; Unfallchirurg 1993; 96: 508-516 |
Original publications without mentioning of personal name
| V Ferber L, Köster I, Hauner H;
Medical costs of diabetic comlications total costs and exess costs by age
and type of treatment: Results of the German CoDiM study; Exp Clin
Endocrinol Diabetes; 2007; 115, 97-104 |
| Köster I, von Ferber L, Ihle P,
Schubert I, Hauner H; The cost burden of diabetes mellitus: the evidence
from Germany-the CoDiM Study; Diabetologia 2006; 49, 1498-1504 |
| Köster I, Hauner H, v Freber L;
Heterogenität der Kosten bei Patienten mit Diabetes mellitus: Die
KoDim-Studie; Dtsch Med Wochenschr; 2006; 131, 804-810 |
| V Ferber L, Köster I, Hauner H;
Kosten der antihyperglykänischen Behandlung des Diabetes mellitus;
Med Klin; 2006; 101, 384-393 |
| Middecke M, Hauner H;
Diabetes im Spannungsfeld zwischen evidenzbasierter Medizin und
Praxisalltag; Dtsch Med Wochenschr; 2005; 130, S59-S94 |
| Schöffski O;
Nutzenbewertung von Arzneimitteln und Gesundheitsökonomie;
Gesund ökom Qual manag; 2005; Supp2, S27-S69 |
Oral Presentations
| Müller E, Huppertz E, Stridde E;
Comparing British and German diabetes guidelines with respect to longterm
outcomes and associated costs: Results from the EAGLE diabetes simulation
model; 2007, ISPOR, DB2 |
| Breitscheidel L, Kreyenberg K, Stridde E,
Benter U, Eichmann F; Backpain in Germany: Are there differences
concerning health-related QoL in patients treated according to guidelines,
guideline independent and patient self-treatment; 2007, ISPOR, PR4 |
| Pittrow D, Pieper L, Klotsche J, Eichler T,
Huppertz E, Stridde E, Lehnert H, Wittchen HU; Mikro- und
makrovaskuläre Folgeerkrankungen bei Typ 2 Diabetikern in der
primärärztlichen Versorgung: Ergebnisse der DETECT Studie;
Diabetologie und Stoffwechsel; 2007, S1-S142, V5 |
| Müller E, Huppertz E, Stridde E;
Vergleich der deutschen und britischen Diabetesleitlinien: Auftreten von
Spätkomplikationen und daraus resultierenden Kosten: Simulation mit
dem EAGLE Modell; Diabetologie und Stoffwechsel; 2007, S1-S142, V28 |
|
Deutsch